O.H. Frazier, MD

O. H. Frazier, M.D., is a living legend and celebrated for his contributions to the field of mechanical circulatory support and pioneering treatments for patients suffering from heart failure. He performed over 1,200 heart transplants and implanted more than 900 left ventricular assist devices, more than any other surgeon in the world. Today he serves as the Co-Director of Center for Preclinical Surgical & Interventional Research at THI.

Show full bio

For more than 30 years, Dr. O. H. Frazier has been a pioneer in the treatment of severe heart failure and in the fields of heart transplantation and artificial devices that may be used either to substitute for or assist the pumping action of the human heart. As a result of his work, he become one of the top transplantation and mechanical circulatory support surgeons in the world. Dr. Frazier performed over 1,200 heart transplants and implanted more than 900 left ventricular assist devices, more than any other surgeon in the world.

Dr. Frazier’s interest in mechanical circulatory support began in 1969, when, as a student at Baylor College of Medicine, he wrote a research paper about the experimental total artificial heart, which was first implanted in 1969 by Dr. Denton Cooley. Throughout the 1970s and 1980s, Dr. Frazier continued experimental work toward developing an implantable left ventricular assist device (LVAD) to aid the failing heart.In 2011, Dr. Frazier implanted the first successful continuous-flow total artificial heart using two second generation HeartMate II LVADs to replace a patient’s failing heart.

See Publications

Texas Heart Institute Positions

Current Projects

Interests

Education

  • Undergraduate:

    University of Texas

  • Medical School:

    Baylor College of Medicine

  • Residency:

    Baylor College of Medicine

  • Fellowships:

    Texas Heart Institute/Baylor College of Medicine

Academic & Clinical Affiliations

  • Baylor College of Medicine
  • Baylor St. Luke's Medical Center

Certifications

  • American Board of Thoracic Surgery
  • American Board of Surgery

Honors, Awards and Memberships

Publications

4862227 SE7HDD49 1 alternatives-to-animal-experimentation 10 date desc Frazier 1910 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%223IBIF8RJ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nissim%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BNissim%2C%20L.%2C%20Karnik%2C%20S.%2C%20Smith%2C%20P.%20A.%20et%20al.%20%282023%29.%20Machine%20learning%20based%20on%20computational%20fluid%20dynamics%20enables%20geometric%20design%20optimisation%20of%20the%20NeoVAD%20blades.%20%26lt%3Bi%26gt%3BSci%20Rep%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B13%26lt%3B%5C%2Fi%26gt%3B%2C%207183.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-33708-9%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-33708-9%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Machine%20learning%20based%20on%20computational%20fluid%20dynamics%20enables%20geometric%20design%20optimisation%20of%20the%20NeoVAD%20blades%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%22%2C%22lastName%22%3A%22Nissim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shweta%22%2C%22lastName%22%3A%22Karnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Alex%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yaxin%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20Howard%22%2C%22lastName%22%3A%22Frazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharine%20H.%22%2C%22lastName%22%3A%22Fraser%22%7D%5D%2C%22abstractNote%22%3A%22The%20NeoVAD%20is%20a%20proposed%20paediatric%20axial-flow%20Left%20Ventricular%20Assist%20Device%20%28LVAD%29%2C%20small%20enough%20to%20be%20implanted%20in%20infants.%20The%20design%20of%20the%20impeller%20and%20diffuser%20blades%20is%20important%20for%20hydrodynamic%20performance%20and%20haemocompatibility%20of%20the%20pump.%20This%20study%20aimed%20to%20optimise%20the%20blades%20for%20pump%20efficiency%20using%20Computational%20Fluid%20Dynamics%20%28CFD%29%2C%20machine%20learning%20and%20global%20optimisation.%20Meshing%20of%20each%20design%20typically%20included%206%20million%20hexahedral%20elements%20and%20a%20Shear%20Stress%20Transport%20turbulence%20model%20was%20used%20to%20close%20the%20Reynolds%20Averaged%20Navier-Stokes%20equations.%20CFD%20models%20of%2032%20base%20geometries%2C%20operating%20at%208%20flow%20rates%20between%200.5%20and%204%5Cu00a0L%5C%2Fmin%2C%20were%20created%20to%20match%20experimental%20studies.%20These%20were%20validated%20by%20comparison%20of%20the%20pressure-flow%20and%20efficiency-flow%20curves%20with%20those%20experimentally%20measured%20for%20all%20base%20prototype%20pumps.%20A%20surrogate%20model%20was%20required%20to%20allow%20the%20optimisation%20routine%20to%20conduct%20an%20efficient%20search%3B%20a%20multi-linear%20regression%2C%20Gaussian%20Process%20Regression%20and%20a%20Bayesian%20Regularised%20Artificial%20Neural%20Network%20predicted%20the%20optimisation%20objective%20at%20design%20points%20not%20explicitly%20simulated.%20A%20Genetic%20Algorithm%20was%20used%20to%20search%20for%20an%20optimal%20design.%20The%20optimised%20design%20offered%20a%205.51%25%20increase%20in%20efficiency%20at%20design%20point%20%28a%2020.9%25%20performance%20increase%29%20as%20compared%20to%20the%20best%20performing%20pump%20from%20the%2032%20base%20designs.%20An%20optimisation%20method%20for%20the%20blade%20design%20of%20LVADs%20has%20been%20shown%20to%20work%20for%20a%20single%20objective%20function%20and%20future%20work%20will%20consider%20multi-objective%20optimisation.%22%2C%22date%22%3A%222023-05-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-023-33708-9%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T13%3A54%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22AFQ395YW%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Devich%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDevich%2C%20R.%2C%20Neuendorff%2C%20N.%20R.%2C%20%26lt%3Bstrong%26gt%3BFrazier%26lt%3B%5C%2Fstrong%26gt%3B%2C%20O.%20H.%20et%20al.%20%282023%29.%20Hematopoietic%20stimulation%20during%20Impella%205.5%20support%20to%20avoid%20transfusions%20in%20a%20Jehovah%26%23x2019%3Bs%20Witness.%20%26lt%3Bi%26gt%3BASAIO%20J%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001944%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001944%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hematopoietic%20stimulation%20during%20Impella%205.5%20support%20to%20avoid%20transfusions%20in%20a%20Jehovah%27s%20Witness%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Devich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nina%20Rosa%22%2C%22lastName%22%3A%22Neuendorff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oscar%20Howard%22%2C%22lastName%22%3A%22Frazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Howard%20J.%22%2C%22lastName%22%3A%22Eisen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Dowling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miriam%22%2C%22lastName%22%3A%22Freundt%22%7D%5D%2C%22abstractNote%22%3A%22The%20population%20presenting%20with%20cardiogenic%20shock%20is%20heterogenous.%20Anemia%20is%20common%20in%20advanced%20heart%20failure%20and%20associated%20with%20poor%20outcomes.%20Microaxial%20flow%20pumps%20may%20cause%20ongoing%20blood%20trauma%20and%20worsen%20anemia.%20Treatment%20with%20recombinant%20erythropoietin%2C%20iron%2C%20vitamin%20B%2C%20and%20folate%20is%20recommended%20before%20cardiac%20surgery%20to%20reduce%20perioperative%20transfusion%20requirements%20but%20no%20data%20exist%20on%20the%20feasibility%20and%20safety%20during%20support%20with%20microaxial%20flow%20pumps.%20This%20novel%20strategy%20was%20born%20out%20of%20necessity%20to%20support%20a%20Jehovah%26%23039%3Bs%20Witness%20who%20opposes%20blood%20transfusion%20but%20required%20mechanical%20circulatory%20support.%20We%20present%20its%20efficacy%20over%20the%20duration%20of%2019%20days%20of%20Impella%205.5%20support%20where%20hemoglobin%20level%20remained%20stable%2C%20and%20platelet%20count%20significantly%20improved%20despite%20a%20brief%20episode%20of%20gastrointestinal%20bleeding.%20No%20thromboembolic%20complications%20occurred.%20We%20anticipate%20this%20strategy%20could%20help%20not%20only%20Jehovah%26%23039%3Bs%20Witnesses%2C%20but%20also%20patients%20awaiting%20cardiac%20transplantation%20since%20transfusions%20stimulate%20development%20of%20antibodies%20which%20may%20preclude%20or%20postpone%20finding%20a%20suitable%20donor%20organ.%20Furthermore%2C%20it%20may%20minimize%20or%20prevent%20perioperative%20needs%20for%20transfusions%20for%20patients%20being%20bridged%20to%20durable%20left%20ventricular%20assist%20devices.%22%2C%22date%22%3A%222023-04-24%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FMAT.0000000000001944%22%2C%22ISSN%22%3A%221538-943X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%225WVJH2TN%22%5D%2C%22dateModified%22%3A%222023-06-08T14%3A35%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22GSMKVAHI%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chu%20et%20al.%22%2C%22parsedDate%22%3A%222023-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChu%2C%20M.%20W.%20A.%2C%20Ruel%2C%20M.%2C%20Graeve%2C%20A.%20et%20al.%20%282023%29.%20Low-dose%20vs%20standard%20Warfarin%20after%20mechanical%20mitral%20valve%20replacement%3A%20a%26%23xA0%3Brandomized%20trial.%20%26lt%3Bi%26gt%3BAnn%20Thorac%20Surg%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B115%26lt%3B%5C%2Fi%26gt%3B%2C%20929%26%23x2013%3B938.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2022.12.031%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.athoracsur.2022.12.031%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Low-dose%20vs%20standard%20Warfarin%20after%20mechanical%20mitral%20valve%20replacement%3A%20a%5Cu00a0randomized%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20W.%20A.%22%2C%22lastName%22%3A%22Chu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Ruel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allen%22%2C%22lastName%22%3A%22Graeve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20W.%22%2C%22lastName%22%3A%22Gerdisch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20J.%22%2C%22lastName%22%3A%22Damiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20L.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20Brent%22%2C%22lastName%22%3A%22Keeling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Wait%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20C.%22%2C%22lastName%22%3A%22Hagberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reed%20D.%22%2C%22lastName%22%3A%22Quinn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gulshan%20K.%22%2C%22lastName%22%3A%22Sethi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosario%22%2C%22lastName%22%3A%22Floridia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20J.%22%2C%22lastName%22%3A%22Barreiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20L.%22%2C%22lastName%22%3A%22Pruitt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20D.%22%2C%22lastName%22%3A%22Accola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Dagenais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%20H.%22%2C%22lastName%22%3A%22Markowitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jian%22%2C%22lastName%22%3A%22Ye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20E.%22%2C%22lastName%22%3A%22Sekela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryan%20Y.%22%2C%22lastName%22%3A%22Tsuda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Duncan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20G.%22%2C%22lastName%22%3A%22Swistel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lacy%20E.%22%2C%22lastName%22%3A%22Harville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20J.%22%2C%22lastName%22%3A%22DeRose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20J.%22%2C%22lastName%22%3A%22Lehr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20H.%22%2C%22lastName%22%3A%22Alexander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20D.%22%2C%22lastName%22%3A%22Puskas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22PROACT%20Mitral%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Current%20guidelines%20recommend%20a%20target%20international%20normalized%20ratio%20%28INR%29%20range%20of%202.5%20to%203.5%20in%20patients%20with%20a%20mechanical%20mitral%20prosthesis.%20The%20Prospective%20Randomized%20On-X%20Anticoagulation%20Clinical%20Trial%20%28PROACT%29%20Mitral%20randomized%20controlled%20noninferiority%20trial%20assessed%20safety%20and%20efficacy%20of%20warfarin%20at%20doses%20lower%20than%20currently%20recommended%20in%20patients%20with%20an%20On-X%20%28Artivion%2C%20Inc%29%20mechanical%20mitral%20valve.%5CnMETHODS%3A%20After%20On-X%20mechanical%20mitral%20valve%20replacement%2C%20followed%20by%20at%20least%203%20months%20of%20standard%20anticoagulation%2C%20401%20patients%20at%2044%20North%20American%20centers%20were%20randomized%20to%20low-dose%20warfarin%20%28target%20INR%2C%202.0-2.5%29%20or%20standard-dose%20warfarin%20%28target%20INR%2C%202.5-3.5%29.%20All%20patients%20were%20prescribed%20aspirin%2C%2081%20mg%20daily%2C%20and%20encouraged%20to%20use%20home%20INR%20testing.%20The%20primary%20end%20point%20was%20the%20sum%20of%20the%20linearized%20rates%20of%20thromboembolism%2C%20valve%20thrombosis%2C%20and%20bleeding%20events.%20The%20design%20was%20based%20on%20an%20expected%207.3%25%20event%20rate%20and%201.5%25%20noninferiority%20margin.%5CnRESULTS%3A%20Mean%20patient%20follow-up%20was%204.1%20years.%20Mean%20INR%20was%202.47%20and%202.92%20%28P%20%26lt%3B.001%29%20in%20the%20low-dose%20and%20standard-dose%20warfarin%20groups%2C%20respectively.%20Primary%20end%20point%20rates%20were%2011.9%25%20per%20patient-year%20in%20the%20low-dose%20group%20and%2012.0%25%20per%20patient-year%20in%20the%20standard-dose%20group%20%28difference%2C%5Cu00a0-0.07%25%3B%2095%25%20CI%2C%5Cu00a0-3.40%25%20to%203.26%25%29.%20The%20CI%20%26gt%3B1.5%25%2C%20thus%20noninferiority%20was%20not%20achieved.%20Rates%20%28percentage%20per%20patient-year%29%20of%20the%20individual%20components%20of%20the%20primary%20end%20point%20were%202.3%25%20vs%202.5%25%20for%20thromboembolism%2C%200.5%25%20vs%200.5%25%20for%20valve%20thrombosis%2C%20and%209.13%25%20vs%209.04%25%20for%20bleeding.%5CnCONCLUSIONS%3A%20Compared%20with%20standard-dose%20warfarin%2C%20low-dose%20warfarin%20did%20not%20achieve%20noninferiority%20for%20the%20composite%20primary%20end%20point.%20%28PROACT%20Clinicaltrials.gov%20number%2C%20NCT00291525%29.%22%2C%22date%22%3A%222023-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.athoracsur.2022.12.031%22%2C%22ISSN%22%3A%221552-6259%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%22BNSCCUCI%22%5D%2C%22dateModified%22%3A%222023-06-08T14%3A11%3A37Z%22%7D%7D%2C%7B%22key%22%3A%2252IGJJ59%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Smith%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSmith%2C%20P.%20A.%2C%20Wang%2C%20Y.%20and%20%26lt%3Bstrong%26gt%3BFrazier%26lt%3B%5C%2Fstrong%26gt%3B%2C%20O.%20H.%20%282023%29.%20The%20evolution%20of%20durable%2C%20implantable%20axial-flow%20rotary%20blood%20pumps.%20%26lt%3Bi%26gt%3BTex%20Heart%20Inst%20J%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B50%26lt%3B%5C%2Fi%26gt%3B%2C%20e227908.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-22-7908%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-22-7908%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20evolution%20of%20durable%2C%20implantable%20axial-flow%20rotary%20blood%20pumps%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Alex%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yaxin%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20H.%22%2C%22lastName%22%3A%22Frazier%22%7D%5D%2C%22abstractNote%22%3A%22Left%20ventricular%20assist%20devices%20%28LVADs%29%20are%20increasingly%20used%20to%20treat%20patients%20with%20end-stage%20heart%20failure.%20Implantable%20LVADs%20were%20initially%20developed%20in%20the%201960s%20and%201970s.%20Because%20of%20technological%20constraints%2C%20early%20LVADs%20had%20limited%20durability%20%28eg%2C%20membrane%20or%20valve%20failure%29%20and%20poor%20biocompatibility%20%28eg%2C%20driveline%20infections%20and%20high%20rates%20of%20hemolysis%20caused%20by%20high%20shear%20rates%29.%20As%20the%20technology%20has%20improved%20over%20the%20past%2050%20years%2C%20contemporary%20rotary%20LVADs%20have%20become%20smaller%2C%20more%20durable%2C%20and%20less%20likely%20to%20result%20in%20infection.%20A%20better%20understanding%20of%20hemodynamics%20and%20end-organ%20perfusion%20also%20has%20driven%20research%20into%20the%20enhanced%20functionality%20of%20rotary%20LVADs.%20This%20paper%20reviews%20from%20a%20historical%20perspective%20some%20of%20the%20most%20influential%20axial-flow%20rotary%20blood%20pumps%20to%20date%2C%20from%20benchtop%20conception%20to%20clinical%20implementation.%20The%20history%20of%20mechanical%20circulatory%20support%20devices%20includes%20improvements%20related%20to%20the%20mechanical%2C%20anatomical%2C%20and%20physiologic%20aspects%20of%20these%20devices.%20In%20addition%2C%20areas%20for%20further%20improvement%20are%20discussed%2C%20as%20are%20important%20future%20directions-such%20as%20the%20development%20of%20miniature%20and%20partial-support%20LVADs%2C%20which%20are%20less%20invasive%20because%20of%20their%20compact%20size.%20The%20ongoing%20development%20and%20optimization%20of%20these%20pumps%20may%20increase%20long-term%20LVAD%20use%20and%20promote%20early%20intervention%20in%20the%20treatment%20of%20patients%20with%20heart%20failure.%22%2C%22date%22%3A%222023-03-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.14503%5C%2FTHIJ-22-7908%22%2C%22ISSN%22%3A%221526-6702%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T18%3A04%3A19Z%22%7D%7D%2C%7B%22key%22%3A%222NEUX2CW%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kiang%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-24%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKiang%2C%20S.%2C%20Nissim%2C%20L.%2C%20Tedesco%2C%20V.%20et%20al.%20%282022%29.%20Modeling%20a%20magnetic%20levitation%20bearing%20with%20CFD%20hemocompatibility%20optimization.%20In%20%26lt%3Bi%26gt%3B2022%20IEEE%2020th%20Biennial%20Conference%20on%20Electromagnetic%20Field%20Computation%20%28CEFC%29%26lt%3B%5C%2Fi%26gt%3B%20%281%26%23x2013%3B2%29.%20Denver%2C%20CO%2C%20USA%3A%20IEEE.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1109%5C%2FCEFC55061.2022.9940768%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1109%5C%2FCEFC55061.2022.9940768%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22conferencePaper%22%2C%22title%22%3A%22Modeling%20a%20magnetic%20levitation%20bearing%20with%20CFD%20hemocompatibility%20optimization%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Kiang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%22%2C%22lastName%22%3A%22Nissim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Tedesco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eiji%22%2C%22lastName%22%3A%22Ogiwara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katherine%22%2C%22lastName%22%3A%22Fraser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nobuyuki%22%2C%22lastName%22%3A%22Kurita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.H.%22%2C%22lastName%22%3A%22Frazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yaxin%22%2C%22lastName%22%3A%22Wang%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Oct%2024%202022%22%2C%22proceedingsTitle%22%3A%222022%20IEEE%2020th%20Biennial%20Conference%20on%20Electromagnetic%20Field%20Computation%20%28CEFC%29%22%2C%22conferenceName%22%3A%222022%20IEEE%2020th%20Biennial%20Conference%20on%20Electromagnetic%20Field%20Computation%20%28CEFC%29%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1109%5C%2FCEFC55061.2022.9940768%22%2C%22ISBN%22%3A%22978-1-66546-833-6%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fieeexplore.ieee.org%5C%2Fdocument%5C%2F9940768%5C%2F%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%224IAB3NJ4%22%2C%22N5HQ4VYL%22%2C%22QF52JASW%22%5D%2C%22dateModified%22%3A%222022-12-01T19%3A18%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22D38AM2DM%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Moctezuma-Ramirez%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-18%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMoctezuma-Ramirez%2C%20A.%2C%20Elgalad%2C%20A.%2C%20Handy%2C%20K.%20et%20al.%20%282022%29.%20Baseline%20hemodynamics%20including%20aortic%20and%20pulmonary%20blood%20flow%20in%20a%20chronic%20bovine%20model.%20%26lt%3Bi%26gt%3BSurgeries%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B3%26lt%3B%5C%2Fi%26gt%3B%2C%20192%26%23x2013%3B202.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fsurgeries3030021%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fsurgeries3030021%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Baseline%20hemodynamics%20including%20aortic%20and%20pulmonary%20blood%20flow%20in%20a%20chronic%20bovine%20model%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angel%22%2C%22lastName%22%3A%22Moctezuma-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdelmotagaly%22%2C%22lastName%22%3A%22Elgalad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%22%2C%22lastName%22%3A%22Handy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gil%22%2C%22lastName%22%3A%22Costas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20H.%22%2C%22lastName%22%3A%22Frazier%22%7D%5D%2C%22abstractNote%22%3A%22The%20use%20of%20large%20animal%20models%20in%20the%20preclinical%20setting%20has%20expanded%20and%20become%20increasingly%20valuable%20for%20evaluating%20the%20safety%20and%20efficacy%20of%20new%20therapies%20and%20devices.%20Here%2C%20we%20report%20normal%20hemodynamic%20values%2C%20including%20aortic%20and%20pulmonary%20blood%20flow%2C%20in%20a%20bovine%20model%20at%20rest%20and%20during%20exercise%20after%20a%20control%20procedure.%20We%20performed%20a%20left%20lateral%20thoracotomy%20and%20implanted%20fluid-filled%20pressure%20lines%20%28aortic%20pressure%2C%20right%20atrial%20pressure%2C%20left%20atrial%20pressure%2C%20pulmonary%20artery%20pressure%29%20and%20left%20%28systemic%29%20and%20right%20%28pulmonary%29%20flow%20probe%20lines.%20Throughout%20the%20postoperative%20period%2C%20the%20calf%5Cu2019s%20physiologic%20pressures%2C%20vital%20signs%2C%20aortic%20and%20pulmonary%20blood%20flow%2C%20and%20pulmonary%20and%20systemic%20vascular%20resistance%20were%20recorded%20hourly%20at%20rest%20and%20during%20treadmill%20exercise%20evaluations.%20When%20pressures%20and%20flow%20rates%20at%20baseline%20and%20during%20treadmill%20trials%20were%20compared%2C%20we%20observed%20a%20physiologic%20response%20to%20exercise%20similar%20to%20that%20seen%20in%20humans%2C%20with%20a%20sympathetic%20discharge%20that%20increased%20systolic%20blood%20pressure.%20However%2C%20the%20rise%20in%20mean%20arterial%20pressure%20was%20much%20lower%20due%20to%20an%20overall%20decrease%20in%20vascular%20resistance%2C%20which%20increased%20blood%20flow.%20This%20study%20provides%20investigators%2C%20device%20engineers%2C%20and%20manufacturers%20with%20normal%20bovine%20cardiovascular%20physiology%20data%20that%20can%20be%20used%20for%20technical%20consideration%20during%20device%20development%20for%20preclinical%20trials.%22%2C%22date%22%3A%22Jul%2018%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fsurgeries3030021%22%2C%22ISSN%22%3A%222673-4095%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2673-4095%5C%2F3%5C%2F3%5C%2F21%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%22CA7YD8T8%22%2C%22QZHY2RIG%22%2C%22DGFQCQPP%22%2C%222RCWVZ4F%22%2C%22SMXIUQ9G%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A38%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22Q3J2QFZY%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Selzman%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSelzman%2C%20C.%20H.%2C%20Feller%2C%20E.%20D.%2C%20Walker%2C%20J.%20C.%20et%20al.%20%282022%29.%20The%20Jarvik%202000%20left%20ventricular%20assist%20device%3A%20Results%20of%20the%20United%20States%20Bridge%20to%20Transplant%20Trial.%20%26lt%3Bi%26gt%3BASAIO%20J%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001750%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001750%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Jarvik%202000%20left%20ventricular%20assist%20device%3A%20Results%20of%20the%20United%20States%20Bridge%20to%20Transplant%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Craig%20H.%22%2C%22lastName%22%3A%22Selzman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erika%20D.%22%2C%22lastName%22%3A%22Feller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jordan%20C.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%20C.%22%2C%22lastName%22%3A%22Sheridan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20C.%22%2C%22lastName%22%3A%22Silvestry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20C.%22%2C%22lastName%22%3A%22Daly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anelechi%20C.%22%2C%22lastName%22%3A%22Anyanwu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Madigan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ping-Yu%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20Howard%22%2C%22lastName%22%3A%22Frazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ulrich%20P.%22%2C%22lastName%22%3A%22Jorde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bartley%20P.%22%2C%22lastName%22%3A%22Griffith%22%7D%5D%2C%22abstractNote%22%3A%22The%20Jarvik%202000%20bridge%20to%20transplant%20investigational%20device%20exemption%20study%20was%20a%20multicentered%2C%20prospective%20study%20of%20150%20UNOS%20status%20I%20patients%20implanted%20with%20the%20Jarvik%202000%20between%202005%20and%202012.%20During%20the%20study%20period%2C%20there%20were%20numerous%20modifications%20of%20the%20system%20that%20included%20converting%20from%20pin%20to%20cone%20bearings.%20Results%20were%20analyzed%20for%20three%20cohorts%3A%20total%20%28n%20%3D%20150%29%2C%20pin%20%28n%20%3D%20128%29%2C%20and%20cone%20%28n%20%3D%2022%29.%20Baseline%20demographics%20included%20age%20%2852%5Cu2009%5Cu00b1%5Cu200913%29%2C%20gender%20%2879%25%20male%29%2C%20size%20%28body%20surface%20area%201.98%29%2C%20and%20etiology%20%2837%25%20idiopathic%20dilated%20cardiomyopathy%3B%2043%25%20Ischemic%29.%20Seventy%20percent%20of%20patients%20were%20either%20INTERMACS%201%20or%202.%20The%20primary%20endpoint-defined%20as%20successful%20transplantation%20or%20listing%20at%20180%20days%20%28prespecified%20at%2065%25%3B%2095%25%20lower%20CI%3A%2057%25%29-was%20successfully%20achieved%20for%20the%20total%20cohort%20%2867.3%25%3B%2095%25%20CI%3A%2059.5%25-74.3%25%3B%20p%20%3D%200.006%29.%20In%20subgroup%20analysis%20of%20the%20more%20contemporary%2C%20cone-bearing%20group%2C%20the%20primary%20endpoint%20was%20met%20in%2091%25%20%2895%25%20CI%3A%2072%25-97.5%25%3B%20p%20%3D%200.001%29.%20Compared%20with%20pin%20patients%2C%20cone-bearing%20patients%20had%20less%20hemolysis%20as%20well%20as%20decreased%20end-organ%20dysfunction.%20Functional%20and%20quality%20of%20life%20scores%20improved%20after%20implantation%20independent%20type%20of%20bearing.%20In%20conclusion%2C%20despite%20a%20particularly%20sick%20patient%20population%2C%20the%20Jarvik%202000%20was%20shown%20to%20be%20effective%20in%20supporting%20the%20advanced%20HF%20patient.%22%2C%22date%22%3A%22Apr%2013%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FMAT.0000000000001750%22%2C%22ISSN%22%3A%221538-943X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%22ZH6PLEMG%22%5D%2C%22dateModified%22%3A%222022-05-04T15%3A36%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22X9LRAGJ4%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Broda%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBroda%2C%20C.%20R.%2C%20Frankel%2C%20W.%20C.%2C%20Nair%2C%20A.%20P.%20et%20al.%20%282022%29.%20Continuous-flow%20ventricular%20assist%20device%20support%20in%20adult%20congenital%20heart%20disease%3A%20A%2015-year%2C%20multicenter%20experience%20of%20temporary%20and%20durable%20support.%20%26lt%3Bi%26gt%3BASAIO%20J%26lt%3B%5C%2Fi%26gt%3B.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001853%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001853%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Continuous-flow%20ventricular%20assist%20device%20support%20in%20adult%20congenital%20heart%20disease%3A%20A%2015-year%2C%20multicenter%20experience%20of%20temporary%20and%20durable%20support%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20R.%22%2C%22lastName%22%3A%22Broda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20C.%22%2C%22lastName%22%3A%22Frankel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%20P.%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20Jeffrey%22%2C%22lastName%22%3A%22Dreyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hari%20P.%22%2C%22lastName%22%3A%22Tunuguntla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20Howard%22%2C%22lastName%22%3A%22Frazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20J.%22%2C%22lastName%22%3A%22Dolgner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20M.%22%2C%22lastName%22%3A%22Anders%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%20C.%22%2C%22lastName%22%3A%22Tume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Athar%20M.%22%2C%22lastName%22%3A%22Qureshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhaval%20R.%22%2C%22lastName%22%3A%22Parekh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20J.%22%2C%22lastName%22%3A%22Hickey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iki%22%2C%22lastName%22%3A%22Adachi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20B.%22%2C%22lastName%22%3A%22Civitello%22%7D%5D%2C%22abstractNote%22%3A%22Heart%20failure%20%28HF%29%20is%20common%20in%20adult%20congenital%20heart%20disease%20%28ACHD%29%20patients%3B%20however%2C%20use%20of%20continuous-flow%20ventricular%20assist%20devices%20%28CF-VADs%29%20remains%20rare.%20We%20reviewed%20outcomes%20of%20patients%20with%20congenital%20heart%20disease%20greater%20than%20or%20equal%20to%2018%20years%20of%20age%20at%20the%20time%20of%20CF-VAD%20implant%20at%20the%20affiliated%20pediatric%20and%20adult%20institutions%20between%202006%20and%202020.%20In%20total%2C%2018%20ACHD%20patients%20%2815%20with%20great%20anatomical%20complexity%29%20received%2021%20CF-VADs.%20Six%20patients%20%28median%20age%2034%20years%29%20received%20seven%20percutaneous%20CF-VADs%20with%20a%20median%20duration%20of%20support%20of%2020%20days%20%283%5Cu201344%20days%29%20with%20all%20patients%20survived%20to%20hospital%20discharge%20and%20two%20patients%20were%20bridged%20to%20durable%20CF-VADs.%20Fourteen%20patients%20%28median%20age%2038%20years%29%20received%20durable%20CF-VADs.%20Thirteen%20patients%20%2893%25%29%20survived%20to%20hospital%20discharge%20and%20the%20median%20duration%20of%20support%20was%2025.8%20months%20%286.4%5Cu201352.1%20months%29.%20Estimated%20survival%20on%20durable%20CF-VAD%20at%201%2C%203%2C%20and%205%20years%20was%2084%25%2C%2072%25%2C%20and%2036%25%2C%20respectively.%20Three%20patients%20were%20successfully%20bridged%20to%20transplantation.%20Device-related%20complications%20include%20cerebrovascular%20accident%20%28n%20%3D%205%29%2C%20driveline%20infection%20%28n%20%3D%203%29%2C%20device%20infection%20requiring%20chronic%20antibiotic%20therapy%20%28n%20%3D%204%29%2C%20gastrointestinal%20bleeding%20%28n%20%3D%206%29%2C%20and%20presumed%20pump%20thrombosis%20%28n%20%3D%205%29.%20These%20results%20show%20percutaneous%20and%20durable%20CF-VADs%20can%20support%20ACHD%20patients%20with%20advanced%20HF.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%221058-2916%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001853%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%229FBUJBMU%22%2C%22S7WF6DG3%22%2C%22QF52JASW%22%5D%2C%22dateModified%22%3A%222023-03-07T22%3A39%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22QY6BEY4P%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lamba%20et%20al.%22%2C%22parsedDate%22%3A%222021-12-30%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLamba%2C%20H.%20K.%2C%20Musfee%2C%20F.%20I.%2C%20Chatterjee%2C%20S.%20et%20al.%20%282021%29.%20The%20influence%20of%20preoperative%20dialysis%20on%20survival%20after%20continuous-flow%20left%20ventricular%20assist%20device%20implantation.%20%26lt%3Bi%26gt%3BInteract%20Cardiovasc%20Thorac%20Surg%26lt%3B%5C%2Fi%26gt%3B%2C%20ivab357.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Ficvts%5C%2Fivab357%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Ficvts%5C%2Fivab357%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20influence%20of%20preoperative%20dialysis%20on%20survival%20after%20continuous-flow%20left%20ventricular%20assist%20device%20implantation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harveen%20K.%22%2C%22lastName%22%3A%22Lamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fadi%20I.%22%2C%22lastName%22%3A%22Musfee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subhasis%22%2C%22lastName%22%3A%22Chatterjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%20P.%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20B.%22%2C%22lastName%22%3A%22Civitello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leo%22%2C%22lastName%22%3A%22Simpson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20H.%22%2C%22lastName%22%3A%22Frazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20V.%22%2C%22lastName%22%3A%22Letsou%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Dialysis%20is%20considered%20a%20contraindication%20to%20continuous-flow%20left%20ventricular%20assist%20device%20%28CF-LVAD%29%20implantation.%20We%20evaluated%20clinical%20outcomes%20and%20survival%20in%20carefully%20selected%2C%20low-risk%20patients%20with%20renal%20failure%20who%20required%20dialysis%20before%20CF-LVAD%20implantation.%5CnMETHODS%3A%20We%20extracted%20medical%20record%20data%20of%20patients%20who%20underwent%20CF-LVAD%20placement%20at%20our%20centre%20between%201%20January%202006%20and%2031%20August%202017%2C%20with%202%20clinical%20scenarios%3A%20those%20who%20required%20long-term%20%28%26gt%3B14%20days%29%20dialysis%20and%20those%20who%20required%20short-term%20%28%5Cu226414%20days%29%20dialysis%20immediately%20before%20implantation.%20Demographic%2C%20clinical%20and%20intraoperative%20characteristics%20and%20survival%20outcomes%20were%20assessed.%5CnRESULTS%3A%20Of%20621%20patients%20who%20underwent%20CF-LVAD%20implantation%20during%20the%20study%20period%2C%2031%20underwent%20dialysis%20beforehand.%20Of%20these%2C%2017%20required%20long-term%20dialysis%20%2813%20haemodialysis%2C%204%20peritoneal%20dialysis%29%2C%20and%2014%20underwent%20short-term%20haemodialysis.%20Compared%20with%20the%20long-term%20dialysis%20patients%2C%20the%20short-term%20dialysis%20patients%20were%20more%20likely%20to%20be%20Interagency%20Registry%20for%20Mechanically%20Assisted%20Circulatory%20Support%20profile%201-2%20%2892.9%25%20vs%2070.6%25%3B%20P%20%26lt%3B%200.001%29%2C%20to%20have%20needed%20preoperative%20mechanical%20circulatory%20support%20%2878.6%25%20vs%2070.6%25%3B%20P%20%26lt%3B%200.01%29%20and%20to%20have%20higher%20in-hospital%20mortality%20%2885.7%25%20vs%2029.4%25%3B%20P%20%3D%200.01%29.%20Patients%20stable%20on%20long-term%20dialysis%20had%20acceptable%20overall%20survival%20and%20markedly%20better%206-month%20and%201-year%20survival%20than%20those%20with%20short-term%20dialysis%20before%20implantation%20%2864.7%25%20vs%2014.3%25%20and%2058.8%25%20vs%207.1%25%2C%20respectively%3B%20P%20%26lt%3B%200.001%29.%5CnCONCLUSIONS%3A%20Carefully%20selected%20patients%20who%20are%20stable%20on%20long-term%20dialysis%20have%20acceptable%20survival%20rates%20after%20CF-LVAD%20implantation.%20Patients%20with%20acute%20renal%20failure%20had%20much%20poorer%20outcomes%20than%20those%20with%20chronic%20end-stage%20renal%20disease.%22%2C%22date%22%3A%22Dec%2030%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Ficvts%5C%2Fivab357%22%2C%22ISSN%22%3A%221569-9285%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%229FBUJBMU%22%2C%22YZAQAZIS%22%2C%22AAQ89W3S%22%2C%22S7WF6DG3%22%2C%22VCK5HVUS%22%2C%22AUPQENLZ%22%5D%2C%22dateModified%22%3A%222022-01-07T20%3A37%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22RN6T936J%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Balachandran%20et%20al.%22%2C%22parsedDate%22%3A%222021-11-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBalachandran%2C%20I.%2C%20%26lt%3Bstrong%26gt%3BFrazier%26lt%3B%5C%2Fstrong%26gt%3B%2C%20O.%20H.%20and%20Rogers%2C%20J.%20G.%20%282021%29.%20Doing%20the%20wrong%20thing%20for%20the%20right%20reasons%3A%20The%20demise%20of%20the%20HVAD.%20%26lt%3Bi%26gt%3BJ%20Thorac%20Cardiovasc%20Surg%26lt%3B%5C%2Fi%26gt%3B%2C%20S0022-5223%2821%2901656%26%23x2013%3B1.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jtcvs.2021.10.058%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jtcvs.2021.10.058%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Doing%20the%20wrong%20thing%20for%20the%20right%20reasons%3A%20The%20demise%20of%20the%20HVAD%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabel%22%2C%22lastName%22%3A%22Balachandran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20H.%22%2C%22lastName%22%3A%22Frazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Nov%2025%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jtcvs.2021.10.058%22%2C%22ISSN%22%3A%221097-685X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SE7HDD49%22%2C%224XZV96J9%22%2C%227DBQSZ99%22%2C%22AUPQENLZ%22%2C%228PULYTSK%22%2C%22X2D36SJL%22%5D%2C%22dateModified%22%3A%222022-01-07T20%3A10%3A20Z%22%7D%7D%5D%7D
Nissim, L., Karnik, S., Smith, P. A. et al. (2023). Machine learning based on computational fluid dynamics enables geometric design optimisation of the NeoVAD blades. Sci Rep 13, 7183. https://doi.org/10.1038/s41598-023-33708-9.
Devich, R., Neuendorff, N. R., Frazier, O. H. et al. (2023). Hematopoietic stimulation during Impella 5.5 support to avoid transfusions in a Jehovah’s Witness. ASAIO J. https://doi.org/10.1097/MAT.0000000000001944.
Chu, M. W. A., Ruel, M., Graeve, A. et al. (2023). Low-dose vs standard Warfarin after mechanical mitral valve replacement: a randomized trial. Ann Thorac Surg 115, 929–938. https://doi.org/10.1016/j.athoracsur.2022.12.031.
Smith, P. A., Wang, Y. and Frazier, O. H. (2023). The evolution of durable, implantable axial-flow rotary blood pumps. Tex Heart Inst J 50, e227908. https://doi.org/10.14503/THIJ-22-7908.
Kiang, S., Nissim, L., Tedesco, V. et al. (2022). Modeling a magnetic levitation bearing with CFD hemocompatibility optimization. In 2022 IEEE 20th Biennial Conference on Electromagnetic Field Computation (CEFC) (1–2). Denver, CO, USA: IEEE. https://doi.org/10.1109/CEFC55061.2022.9940768.
Moctezuma-Ramirez, A., Elgalad, A., Handy, K. et al. (2022). Baseline hemodynamics including aortic and pulmonary blood flow in a chronic bovine model. Surgeries 3, 192–202. https://doi.org/10.3390/surgeries3030021.
Selzman, C. H., Feller, E. D., Walker, J. C. et al. (2022). The Jarvik 2000 left ventricular assist device: Results of the United States Bridge to Transplant Trial. ASAIO J. https://doi.org/10.1097/MAT.0000000000001750.
Broda, C. R., Frankel, W. C., Nair, A. P. et al. (2022). Continuous-flow ventricular assist device support in adult congenital heart disease: A 15-year, multicenter experience of temporary and durable support. ASAIO J. Available at: https://doi.org/10.1097/MAT.0000000000001853.
Lamba, H. K., Musfee, F. I., Chatterjee, S. et al. (2021). The influence of preoperative dialysis on survival after continuous-flow left ventricular assist device implantation. Interact Cardiovasc Thorac Surg, ivab357. https://doi.org/10.1093/icvts/ivab357.
Balachandran, I., Frazier, O. H. and Rogers, J. G. (2021). Doing the wrong thing for the right reasons: The demise of the HVAD. J Thorac Cardiovasc Surg, S0022-5223(21)01656–1. https://doi.org/10.1016/j.jtcvs.2021.10.058.

Recent News

See All

Dr. O.H. Frazier Recognized With Honorary Doctorate by Tarleton State University

Dr. O.H. “Bud” Frazier received an honorary doctorate of humane letters today during Tarleton State’s spring 2025 commencement ceremonies. From...

Read more

Dr. O.H. Frazier Honored With Lifetime Achievement Award by ASAIO

Dr. O.H. “Bud” Frazier has been named recipient of the prestigious Pushpa and Kewal Krishan Gupta Lifetime Achievement Award in Development...

Read more

Dr. O.H. Frazier to Receive Inaugural Pushpa and Kewal Krishan Gupta Lifetime Achievement Award in Development of Therapies for Cardiovascular and Pulmonary Diseases from the ASAIO

The ASAIO Board of Trustees has named Dr. O.H. Frazier, recipient of the prestigious Pushpa and Kewal Krishan Gupta Lifetime...

Read more